As per the report, the Europe Prefilled Syringes Market Size is valued at USD 1.04 billion in 2020 and is expected to grow at a CAGR of 5.77% to reach USD 1.37 billion by 2025 during the forecast period.
A “prefilled syringe” is a syringe filled with a fixed quantity of a therapeutic drug. It is more accurate, affordable, convenient, sterile, safe and accessible as compared to traditional drug delivery methods in which vials were used for storage of pharmaceutical drugs. These vials were prone to dosing errors and contamination while prefilled syringes have no such drawbacks. This format of a parenteral drug delivery system is being adopted by a growing number of healthcare facilities.
Europe prefilled syringes market is progressing aggressively. Europe has its own prefilled syringes market. Rising awareness about safe-injectable syringes, increasing no. of chronic diseases, adoption of biological drugs is increased the prefilled syringes market for the patient treatment. Europe Syringes manufacturer always making improvements into syringes technology & their material also. For the safety purpose, better and more convenient than before manufacturing prefilled syringes. Prefilled syringes are one of the fastest-growing markets in drug delivery in various countries.it gives benefits to the pharmaceutical packaging industries of Europe. Medical professionals, doctors, practitioners have given better response to prefilled syringe technology.
This research report on the Europe Prefilled Syringes Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2025.
Regionally, in 2019, Europe commanded the largest market share. It is expected to remain until the end of the forecast period. The adoption of high safety standards and the presence of a considerable number of market players can be attributed to its dominance in the market.
UK, Germany, France are well-developed countries in Europe. UK and Germany have the largest market share prefilled syringes market in Europe. Ipsen UK & Ireland launched the new pre-filled syringes for the Somatuline Autogel. The specially designed as per the patient-centric. The syringe is used for NHS for the treatment to adult patients with neuroendocrine tumours. Every yr. more than 4000 people are diagnosed with neuroendocrine tumours (NET). In Europe, Dutch hospital is the first in Europe developed re-filled ready to use syringes. This machine will reduce mistakes chances.
Companies like Becton Dickinson and Company, Gerresheimer AG, SCHOTT AG, West Pharmaceutical Services, Inc., Ompi, Catalent, Inc., Weigao Group, Vetter Pharma International GmbH, Nipro Corporation & MedPro Inc. are playing a leading role in the Europe Prefilled Syringes Market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Materials
5.1.1 Introduction
5.1.2 Glass Prefilled Syringes
5.1.3 Plastic Prefilled Syringes
5.1.4 Y-o-Y Growth Analysis, By Materials
5.1.5 Market Attractiveness Analysis, By Materials
5.1.6 Market Share Analysis, By Materials
5.2 Type
5.2.1 Introduction
5.2.2 Conventional Prefilled Syringes
5.2.3 Safety Prefilled Syringes
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 Design
5.3.1 Introduction
5.3.2 Single-Chamber Prefilled Syringes
5.3.3 Dual Chamber Prefilled Syringes
5.3.4 Customized Prefilled Syringes
5.3.5 Y-o-Y Growth Analysis, By Design
5.3.6 Market Attractiveness Analysis, By Design
5.3.7 Market Share Analysis, By Design
5.4 Application
5.4.1 Introduction
5.4.2 Vaccines
5.4.3 Monoclonal Antibodies
5.4.4 Y-o-Y Growth Analysis, By Application
5.4.5 Market Attractiveness Analysis, By Application
5.4.6 Market Share Analysis, By Application
5.5 Distribution Channels
5.5.1 Introduction
5.5.2 Hospitals
5.5.3 Ambulatory Surgical Centres
5.5.4 Mail Order Pharmacies
5.3.5 Y-o-Y Growth Analysis, By Distribution Channels
5.3.6 Market Attractiveness Analysis, By Distribution Channels
5.3.7 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Materials
6.1.3.3 By Type
6.1.3.4 By Design
6.1.3.5 By Application
6.1.3.6 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Materials
6.1.4.3 By Type
6.1.4.4 By Design
6.1.4.5 By Application
6.1.4.6 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Materials
6.1.5.3 By Type
6.1.5.4 By Design
6.1.5.5 By Application
6.1.5.6 By Distribution Channels
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Becton
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dickinson and Company
8.3 Gerresheeimer AG
8.4 SCHOTT AG
8.5 West Pharmaceutical Services
8.6 Ompi
8.7 Catalent Inc.
8.8 Weigao Group
8.9 Vetter Pharma International GmbH
8.10 Nirpo Corporation
8.11 MedPro Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
